Lpath Initiates Dosing In Phase 1 Trial For AMD - First Time Bioactive Lipid Antibody Has Been Dosed In Human Eye

Medical News Today

Lpath, Inc. (OTCBB: LPTN) announced that it has initiated dosing in its Phase 1 clinical trial with iSONEP(TM), the company's drug candidate for age-related macular degeneration (AMD) and possibly for other ocular diseases.